What the business is, and whether it's a good one at a fair price.
Develops and sells branded pharmaceutical formulations for the Indian domestic market, with products across antibiotics (Stergiclav 625 and Smartyclav 625), CNS and psychiatric medications (Sterprax and Stergipam MD), pain management (Stergicet with paracetamol and tramadol), sleep aids (Sterpidem MD with zolpidem), and home healthcare devices including a digital blood pressure monitor. Royal Sense Limited sells all pharmaceutical products as prescription-only medicines under Schedule H classification. Through its wholly-owned subsidiary Stergic Retail Private Limited, the company entered pharmacy retail on 23 February 2026 with the first Stergic Pharmacy counter at Deep Vihar, Rohini Sector-22, Delhi. Consolidated FY26 revenue from operations stood at Rs 103.3759 crore, up 67.4% YoY, while standalone revenue grew 36.7% to Rs 3,778.57 lakhs. The subsidiary contributed Rs 416.76 lakhs to consolidated profit after tax of Rs 657.20 lakhs. Employee costs at 3.7% of revenue and other operating expenses at 4.6% are the disclosed cost lines. A new warehouse in Sonipat was taken on a five-year lease from 1 February 2026 to support distribution.
Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from Royal Sense Limited's filed financials and exchange disclosures
Royal Sense Limited is a Healthcare Equipment & Supplies company listed on BSE.
Effectively yes. It holds ₹3 Cr more cash than debt.
On trailing P/E, Royal Sense Limited ranks 1 of 17 in Medical Equipment & Supplies — cheaper than 100% of them, against an industry median of 20.0×. This is a position, not a valuation judgement.
On a typical session Royal Sense Limited moves 2.89% — that is the median absolute close-to-close move across its last 233 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by Royal Sense Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
